Center-Authored Papers

Filters: Author is LeBlanc, Michael  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
LeBlanc M, Kooperberg C.  2009.  Adaptively weighted association statistics.. Genetic epidemiology. 33(5):442-52. Abstract
Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL.  2016.  Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
B
LeBlanc M, Kooperberg C.  2010.  Boosting predictions of treatment success.. Proceedings of the National Academy of Sciences of the United States of America. 107(31):13559-60.
C
LeBlanc M, Tangen C.  2012.  Choosing Phase II Endpoints and Designs: Evaluating the Possibilities.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(8):2130-2. Abstract
Cook JR, Goldman B, Tubbs RR, Rimsza L, LeBlanc M, Stiff P, Fisher R.  2014.  Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study.. The American journal of surgical pathology. 38(4):494-501. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32. Abstract
Unger JM, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, Hershman DL.  2014.  Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials.. Journal of the National Cancer Institute. Abstract
Kerr KF, LeBlanc M, Janes H.  2017.  Comparisons of cancer staging systems should be based on overall performance in the population.. Clinical trials (London, England). :1740774517722141.
Dazard J-E, Choe M, LeBlanc M, Rao SJ.  2016.  Cross-validation and peeling strategies for survival bump hunting using recursive peeling methods. Statistical Analysis and Data Mining: The ASA Data Science Journal. 9(1):12-42. Abstract
D
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
Schilsky RL, Doroshow JH, LeBlanc M, Conley BA.  2012.  Development and use of integral assays in clinical trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(6):1540-6. Abstract
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SD.  2015.  The diffusion of docetaxel in patients with metastatic prostate cancer.. Journal of the National Cancer Institute. 107(2) Abstract
E
Hoering A, Mitchell A, LeBlanc M, Crowley J.  2013.  Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.. Clinical trials (London, England). Abstract
Unger JM, LeBlanc M, Blanke CD.  2017.  The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.. JAMA oncology. Abstract
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW et al..  2015.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.. Blood. 125(6):992-8. Abstract
F
Persky DO, Dornan D, Goldman B, Braziel R, Fisher R, LeBlanc M, Maloney DG, Press O, Miller T, Rimsza LM.  2012.  Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.. Haematologica. 97(6):937-942. Abstract
G
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
H
Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C et al..  2012.  Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.. Proceedings of the National Academy of Sciences of the United States of America. 109(20):7859-64. Abstract
Philip PA, Chansky K, Rubinstein L, LeBlanc M, Seymour L, Ivy PS, Alberts SR, Catalano PJ, Crowley J.  2014.  Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
I
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
Kooperberg C, LeBlanc M.  2008.  Increasing the power of identifying gene x gene interactions in genome-wide association studies.. Genetic epidemiology. 32(3):255-63. Abstract
Goldman B, LeBlanc M, Crowley J.  2008.  Interim futility analysis with intermediate endpoints.. Clinical trials (London, England). 5(1):14-22. Abstract
L
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L et al..  2015.  Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13):1482-90. Abstract
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD et al..  2015.  Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7):1514-24. Abstract